LAURA PEREZ: Open Payments
NPI 1023309135 · EVERETT, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,209 in 107 payments from 12 companies in 2025. Trend: 2023 $912 · 2024 $1,467 · 2025 $2,209
Food & beverage: $2,209
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $598 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 25 | $492 |
| Collegium Pharmaceutical, Inc. | 12 | $247 |
| Teva Pharmaceuticals USA, Inc. | 8 | $236 |
| Neurocrine BioSciences, Inc. | 11 | $203 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| Supernus Pharmaceuticals, Inc. | 4 | $97 |
| Alkermes, Inc. | 2 | $74 |
| Janssen Pharmaceuticals, Inc | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: VRAYLAR, CAPLYTA, Jornay PM, AUSTEDO XR, INGREZZA, REXULTI, Qelbree, LYBALVI.
Industry payments across WA — which companies pay providers there.
